blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP1377832

EP1377832 - ANTI-IDIOTYPIC ANTIBODY AND ITS USE IN DIAGNOSIS AND THERAPY OF HEPATITIS C VIRUS RELATED DISEASES [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  21.11.2008
Database last updated on 03.09.2024
Most recent event   Tooltip21.11.2008Application deemed to be withdrawnpublished on 24.12.2008  [2008/52]
Applicant(s)For all designated states
Rapid Medical Diagnostic Corporation
650 West Avenue, Suite 2507
Miami Beach, FL 33139 / US
[2004/26]
Former [2004/02]For all designated states
Immune Network Ltd.
3650 Wesbrook Mall
Vancouver, British Columbia V65 2L2 / CA
Inventor(s)01 / GRANT, Michael, D.
Memorial University
St. John's, Newfoundland / CA
 [2004/02]
Representative(s)Gowshall, Jonathan Vallance
Forresters IP LLP
Skygarden
Erika-Mann-Strasse 11
80636 München / DE
[N/P]
Former [2004/02]Gowshall, Jonathan Vallance
Forrester & Boehmert Pettenkoferstrasse 20-22
80336 München / DE
Application number, filing date02716568.702.04.2002
[2004/02]
WO2002CA00416
Priority number, dateUS20010281280P03.04.2001         Original published format: US 281280 P
[2004/02]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO02082089
Date:17.10.2002
Language:EN
[2002/42]
Type: A2 Application without search report 
No.:EP1377832
Date:07.01.2004
Language:EN
The application published by WIPO in one of the EPO official languages on 17.10.2002 takes the place of the publication of the European patent application.
[2004/02]
Search report(s)International search report - published on:EP05.12.2002
ClassificationIPC:G01N33/576, G01N33/68, A61K39/395
[2004/02]
CPC:
G01N33/686 (EP,US); C07K16/4216 (EP,US); C07K16/4225 (EP,US);
G01N33/5767 (EP,US); A61K2039/505 (EP,US)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   TR [2004/02]
Extension statesALNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
RONot yet paid
SINot yet paid
TitleGerman:ANTIIDIOTYP ANTIKÖRPER SOWIE DESSEN VERWENDUNG IN DIAGNOSE UND THERAPIE VON MIT HEPATITIS C VIRUS IN ZUSAMMENHANG STEHENDER KRANKHEITEN[2004/02]
English:ANTI-IDIOTYPIC ANTIBODY AND ITS USE IN DIAGNOSIS AND THERAPY OF HEPATITIS C VIRUS RELATED DISEASES[2004/02]
French:ANTICORPS ANTI-IDIOTYPIQUE ET SON UTILISATION DANS LE DIAGNOSTIC ET LA THERAPIE DE MALADIES LIEES AU VIRUS DE L'HEPATITE C[2004/02]
Entry into regional phase31.10.2003National basic fee paid 
31.10.2003Designation fee(s) paid 
31.10.2003Examination fee paid 
Examination procedure31.10.2003Examination requested  [2004/02]
23.12.2003Amendment by applicant (claims and/or description)
27.01.2006Despatch of a communication from the examining division (Time limit: M06)
22.11.2006Reply to a communication from the examining division
14.12.2007Despatch of a communication from the examining division (Time limit: M06)
25.06.2008Application deemed to be withdrawn, date of legal effect  [2008/52]
01.08.2008Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2008/52]
Request for further processing for:22.11.2006Request for further processing filed
22.11.2006Full payment received (date of receipt of payment)
Request granted
06.12.2006Decision despatched
Fees paidRenewal fee
05.05.2004Renewal fee patent year 03
20.04.2005Renewal fee patent year 04
28.06.2006Renewal fee patent year 05
27.04.2007Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
30.04.200403   M06   Fee paid on   05.05.2004
30.04.200605   M06   Fee paid on   28.06.2006
30.04.200807   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[PX]FR2809106  (ISTAC [FR]) [PX] 1-20 * page 32, paragraph 4; claims 29,32,35 *;
 [YD]US5849583  (MUELLER SYBILLE [US], et al) [YD] 1-20 *claims*;
 [PX]  - GRANT MICHAEL D, "Antibody convergence along a common idiotypic axis in immunodeficiency virus and hepatitis C virus infections.", JOURNAL OF MEDICAL VIROLOGY. UNITED STATES JAN 2002, (200201), vol. 66, no. 1, ISSN 0146-6615, pages 13 - 21, XP001084812 [PX] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1002/jmv.2105
 [Y]  - KENNEDY R C ET AL, "Antigen mimicry by anti-idiotype antibodies that recognize a common anti-hepatitis B surface antigen idiotype.", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY. UNITED STATES 1985, (1985), vol. 185, ISSN 0065-2598, pages 139 - 147, XP001087876 [Y] 1-20 *see esp. page 141, "Characteristics [...]"; "Discussion"*
 [Y]  - NEWS BITES, (200003), URL: www.askemilyss.com/bites/bite0300/imm.htm, (20020624), XP002205111 [Y] 1-20 * abstract *
ExaminationUS6146627
    - "Types of lymphoma", WWW.LYMPHOMATION.ORG, WWW.LYMPHOMATION.ORG, URL: HTTP://WWW.LYMPHOMATION.ORG/TYPES.HTM#AIDS-RELATED
    - BESSON C. ET AL, "Lack of association between HCV infection and HIV-related lymphoma", BRITISH JOURNAL OF HAEMATOLOGY, (1999), vol. 105, pages 568 - 569
    - GRANT M. ET AL, "The anti-idiotypic antibody 1F7 selectively inhibits cytotoxic cells activated in HIV-1 infection", IMMUNOLOGY AND CELL BIOLOGY, (2000), vol. 78, doi:doi:10.1046/j.1440-1711.2000.00879.x, pages 20 - 27, XP002492512

DOI:   http://dx.doi.org/10.1046/j.1440-1711.2000.00879.x
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.